Conduit Pharmaceuticals (CDT) Competitors $1.78 +0.05 (+2.59%) As of 03:14 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CDT vs. PRTG, PPBT, SLXN, VYNE, THAR, CPHI, KTTA, SPRB, BCTX, and XBIOShould you be buying Conduit Pharmaceuticals stock or one of its competitors? The main competitors of Conduit Pharmaceuticals include Portage Biotech (PRTG), Purple Biotech (PPBT), Silexion Therapeutics (SLXN), VYNE Therapeutics (VYNE), Tharimmune (THAR), China Pharma (CPHI), Pasithea Therapeutics (KTTA), Spruce Biosciences (SPRB), Briacell Therap (BCTX), and Xenetic Biosciences (XBIO). These companies are all part of the "pharmaceutical products" industry. Conduit Pharmaceuticals vs. Its Competitors Portage Biotech Purple Biotech Silexion Therapeutics VYNE Therapeutics Tharimmune China Pharma Pasithea Therapeutics Spruce Biosciences Briacell Therap Xenetic Biosciences Portage Biotech (NASDAQ:PRTG) and Conduit Pharmaceuticals (NASDAQ:CDT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment and dividends. Does the media prefer PRTG or CDT? In the previous week, Portage Biotech and Portage Biotech both had 1 articles in the media. Portage Biotech's average media sentiment score of 1.87 equaled Conduit Pharmaceuticals'average media sentiment score. Company Overall Sentiment Portage Biotech Very Positive Conduit Pharmaceuticals Very Positive Is PRTG or CDT more profitable? Company Net Margins Return on Equity Return on Assets Portage BiotechN/A N/A N/A Conduit Pharmaceuticals N/A N/A -435.57% Do institutionals & insiders believe in PRTG or CDT? 13.4% of Portage Biotech shares are owned by institutional investors. Comparatively, 3.3% of Conduit Pharmaceuticals shares are owned by institutional investors. 7.7% of Conduit Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has higher earnings & valuation, PRTG or CDT? Portage Biotech is trading at a lower price-to-earnings ratio than Conduit Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPortage BiotechN/AN/A-$6.77M-$41.65-0.21Conduit PharmaceuticalsN/AN/A-$17.80M-$534.480.00 Which has more risk and volatility, PRTG or CDT? Portage Biotech has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Conduit Pharmaceuticals has a beta of 1.93, meaning that its share price is 93% more volatile than the S&P 500. SummaryPortage Biotech beats Conduit Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Conduit Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CDT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CDT vs. The Competition Export to ExcelMetricConduit PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.27M$2.47B$5.62B$9.81BDividend YieldN/A1.81%4.64%4.14%P/E Ratio0.0022.1430.1125.72Price / SalesN/A729.16463.22174.39Price / CashN/A186.7137.7258.50Price / Book-0.024.498.456.06Net Income-$17.80M$31.61M$3.26B$265.11M7 Day Performance-4.03%2.82%3.34%2.65%1 Month Performance-24.36%4.11%5.72%3.71%1 Year Performance-99.13%7.46%42.58%26.59% Conduit Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CDTConduit Pharmaceuticals0.5869 of 5 stars$1.79+2.6%N/A-99.3%$5.27MN/A0.003Positive NewsGap DownPRTGPortage Biotech0.4739 of 5 stars$5.87+8.3%N/A+189.8%$5.68MN/A-0.146Gap UpPPBTPurple Biotech2.5546 of 5 stars$2.21+1.8%$33.00+1,393.2%N/A$5.61MN/A-0.8420News CoverageEarnings ReportUpcoming EarningsSLXNSilexion TherapeuticsN/A$9.04-2.6%$75.00+729.6%N/A$5.38MN/A0.00N/ANews CoverageEarnings ReportGap UpVYNEVYNE Therapeutics3.041 of 5 stars$0.37+3.5%$6.25+1,611.4%-79.3%$5.37M$500K-0.3730Gap DownTHARTharimmune3.6892 of 5 stars$1.33+7.3%$17.00+1,178.2%-53.0%$5.23MN/A-0.172News CoverageCPHIChina PharmaN/A$1.60-2.4%N/A-92.0%$5.22M$4.30M0.00250News CoverageGap UpHigh Trading VolumeKTTAPasithea Therapeutics1.2354 of 5 stars$0.71+1.7%N/A-85.4%$5.20MN/A-0.073Gap UpSPRBSpruce Biosciences1.9763 of 5 stars$0.12+10.1%$131.25+109,275.0%-70.8%$5.07M$4.91M-0.1320Negative NewsBCTXBriacell Therap1.5758 of 5 stars$0.76+1.5%$32.00+4,138.4%-92.1%$5.04MN/A-0.098Stock SplitGap UpXBIOXenetic Biosciences1.0682 of 5 stars$3.20-0.3%N/A-15.1%$4.96M$2.50M-1.344News CoverageEarnings Report Related Companies and Tools Related Companies Portage Biotech Alternatives Purple Biotech Alternatives Silexion Therapeutics Alternatives VYNE Therapeutics Alternatives Tharimmune Alternatives China Pharma Alternatives Pasithea Therapeutics Alternatives Spruce Biosciences Alternatives Briacell Therap Alternatives Xenetic Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CDT) was last updated on 8/13/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conduit Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conduit Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access